Literature DB >> 26092914

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Dean M Wingerchuk1, Brenda Banwell2, Jeffrey L Bennett2, Philippe Cabre2, William Carroll2, Tanuja Chitnis2, Jérôme de Seze2, Kazuo Fujihara2, Benjamin Greenberg2, Anu Jacob2, Sven Jarius2, Marco Lana-Peixoto2, Michael Levy2, Jack H Simon2, Silvia Tenembaum2, Anthony L Traboulsee2, Patrick Waters2, Kay E Wellik2, Brian G Weinshenker1.   

Abstract

Neuromyelitis optica (NMO) is an inflammatory CNS syndrome distinct from multiple sclerosis (MS) that is associated with serum aquaporin-4 immunoglobulin G antibodies (AQP4-IgG). Prior NMO diagnostic criteria required optic nerve and spinal cord involvement but more restricted or more extensive CNS involvement may occur. The International Panel for NMO Diagnosis (IPND) was convened to develop revised diagnostic criteria using systematic literature reviews and electronic surveys to facilitate consensus. The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG). The core clinical characteristics required for patients with NMOSD with AQP4-IgG include clinical syndromes or MRI findings related to optic nerve, spinal cord, area postrema, other brainstem, diencephalic, or cerebral presentations. More stringent clinical criteria, with additional neuroimaging findings, are required for diagnosis of NMOSD without AQP4-IgG or when serologic testing is unavailable. The IPND also proposed validation strategies and achieved consensus on pediatric NMOSD diagnosis and the concepts of monophasic NMOSD and opticospinal MS.
© 2015 American Academy of Neurology.

Entities:  

Mesh:

Year:  2015        PMID: 26092914      PMCID: PMC4515040          DOI: 10.1212/WNL.0000000000001729

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  59 in total

Review 1.  The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease.

Authors:  Dean M Wingerchuk; Brian G Weinshenker
Journal:  Mult Scler       Date:  2011-12-06       Impact factor: 6.312

Review 2.  Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  Brain Pathol       Date:  2013-11       Impact factor: 6.508

3.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

4.  Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis.

Authors:  Brian G Weinshenker; Dean M Wingerchuk; Sandra Vukusic; Linda Linbo; Sean J Pittock; Claudia F Lucchinetti; Vanda A Lennon
Journal:  Ann Neurol       Date:  2006-03       Impact factor: 10.422

5.  Long-term follow-up of acute partial transverse myelitis.

Authors:  Bertrand Bourre; Hélène Zéphir; Jean-Claude Ongagna; Charlotte Cordonnier; Nicolas Collongues; Stephanie Debette; Marie-Celine Fleury; Olivier Outteryck; Olivier Outerryck; Didier Hannequin; Patrick Vermersch; Jerome de Seze
Journal:  Arch Neurol       Date:  2012-03

6.  The history of neuromyelitis optica.

Authors:  Sven Jarius; Brigitte Wildemann
Journal:  J Neuroinflammation       Date:  2013-01-15       Impact factor: 8.322

7.  Brain abnormalities in neuromyelitis optica.

Authors:  Sean J Pittock; Vanda A Lennon; Karl Krecke; Dean M Wingerchuk; Claudia F Lucchinetti; Brian G Weinshenker
Journal:  Arch Neurol       Date:  2006-03

8.  Occurrence of acute large and edematous callosal lesions in neuromyelitis optica.

Authors:  M Nakamura; T Misu; K Fujihara; I Miyazawa; I Nakashima; T Takahashi; S Watanabe; Y Itoyama
Journal:  Mult Scler       Date:  2009-05-12       Impact factor: 6.312

Review 9.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  862 in total

1.  MOG antibody-related disorders: common features and uncommon presentations.

Authors:  Álvaro Cobo-Calvo; Anne Ruiz; Hyacintha D'Indy; Anne-Lise Poulat; Maryline Carneiro; Nicolas Philippe; Françoise Durand-Dubief; Kumaran Deiva; Sandra Vukusic; Vincent Desportes; Romain Marignier
Journal:  J Neurol       Date:  2017-08-02       Impact factor: 4.849

2.  Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia.

Authors:  Tarig Mohammed Abkur; Eílis Foran; Hugh Kearney; Grace Harkin; Valerie Byrnes; John Lynch
Journal:  J Neurol       Date:  2015-11-21       Impact factor: 4.849

3.  A Urinary Metabolic Signature for Multiple Sclerosis and Neuromyelitis Optica.

Authors:  Teklab Gebregiworgis; Helle H Nielsen; Chandirasegaran Massilamany; Arunakumar Gangaplara; Jay Reddy; Zsolt Illes; Robert Powers
Journal:  J Proteome Res       Date:  2016-01-27       Impact factor: 4.466

4.  Neuromyelitis optica spectrum disorder associated with osmotic demyelination syndrome.

Authors:  Ivan Adamec; Filip Keršić; Luka Crnošija; Mario Habek
Journal:  Neurol Sci       Date:  2016-01-28       Impact factor: 3.307

5.  Demyelinating disease: NMO spectrum disorders: clinical or molecular classification?

Authors:  Sean J Pittock
Journal:  Nat Rev Neurol       Date:  2016-02-05       Impact factor: 42.937

6.  Neuromyelitis optica: an elusive cause of dysphagia.

Authors:  Oliver Cousins; Elena Girelli; Sreedharan Harikrishnan
Journal:  BMJ Case Rep       Date:  2019-01-14

7.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production.

Authors:  Elizabeth Cotzomi; Panos Stathopoulos; Casey S Lee; Alanna M Ritchie; John N Soltys; Fabien R Delmotte; Tyler Oe; Joel Sng; Ruoyi Jiang; Anthony K Ma; Jason A Vander Heiden; Steven H Kleinstein; Michael Levy; Jeffrey L Bennett; Eric Meffre; Kevin C O'Connor
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

8.  Association of CD40 Gene Polymorphisms with Susceptibility to Neuromyelitis Optica Spectrum Disorders.

Authors:  Ziyan Shi; Qin Zhang; Hongxi Chen; Xiaohui Miao; Ju Liu; Zhiyun Lian; Huiru Feng; Hongyu Zhou
Journal:  Mol Neurobiol       Date:  2016-08-30       Impact factor: 5.590

9.  Multifrequency magnetic resonance elastography of the brain reveals tissue degeneration in neuromyelitis optica spectrum disorder.

Authors:  Kaspar-Josche Streitberger; Andreas Fehlner; Florence Pache; Anna Lacheta; Sebastian Papazoglou; Judith Bellmann-Strobl; Klemens Ruprecht; Alexander Brandt; Jürgen Braun; Ingolf Sack; Friedemann Paul; Jens Wuerfel
Journal:  Eur Radiol       Date:  2016-08-29       Impact factor: 5.315

Review 10.  Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica.

Authors:  Jeffrey L Bennett
Journal:  J Neuroophthalmol       Date:  2016-09       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.